Juvenile myelomonocytic leukemia is an aggressive myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Seventy-five percent of patients harbor mutations in the NF1, NRAS, KRAS, or PTPN11 genes, which encode components of Ras signaling networks. Using single nucleotide polymorphism arrays, we identified a region of 11q isodisomy that contains the CBL gene in several JMML samples, and subsequently identified CBL mutations in 27 of 159 JMML samples. Thirteen of these mutations alter codon Y371. In this report, we also demonstrate that CBL and RAS/PTPN11 mutations were mutually exclusive in these patients. CBL mutations are frequent in JMML. Moreover, the exclusivity of CBL mutations with respect to other RAS pathway-associated mutations indicates that CBL may have a role in deregulating this key pathway in JMML.
Introduction
Juvenile myelomonocytic leukemia (JMML) is an aggressive clonal myeloproliferative disorder (MPD) of young children 1, 2 . Extensive molecular data implicate deregulated Ras signaling as a key initiating event in JMML, with 60% of patients harboring somatic PTPN11, NRAS, or KRAS mutations and another 10-15% of cases arising in children with neurofibromatosis type 1 (NF1) and/or showing somatic inactivation of the NF1 tumor suppressor gene 3, 4 . Chronic myelomonocytic leukemia (CMML) shares clinical and laboratory features with JMML, including a high frequency of RAS mutations and a hypersensitive pattern of granulocyte-macrophage colonyforming unit growth (CFU-GM) in response to granulocyte-macrophage colony stimulating factor (GM-CSF) 5, 6, 7, 8 . Moreover, phosphoflow cytometric analysis of CD38 dim /CD14 + /CD33 + cells from JMML and CMML patients recently demonstrated a distinctive pattern of STAT5 hyperphosphorylation in response to low doses of GM-CSF 9 .
Advances in detecting DNA copy number alterations and acquired uniparental isodisomy (UPD) with single nucleotide polymorphism (SNP) arrays have proven fruitful for discovering mutations in other hematologic malignancies 10, 11 . To determine if regions of copy-neutral loss of heterozygosity (LOH) indicative of acquired UPD existed in JMML, we performed Affymetrix SNP 6.0 array analysis on samples from 27 JMML patients with and without known PTPN11, RAS, or NF1 abnormalities. We identified a region of 11q UPD in five of these cases, which includes the CBL gene. Importantly, recent reports uncovered acquired 11q copy-neutral loss-of-heterozygosity (CN-LOH) in related MPDs, and molecular analysis identified CBL mutations in these cases 10, 11 .
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From Furthermore, a few CBL mutations had been reported previously in myeloid malignanices [12] [13] [14] . Based on these observations, we investigated CBL in these five JMML patients with 11q CN-LOH, and detected homozygous mutations in all cases. We then sequenced diagnostic samples from 154 additional JMML patients assembled from a large international cohort and identified 22 more with CBL mutations. We also analyzed a series of 44 patients with CMML who were treated at MD Anderson Cancer Center (MDACC) for mutations and detected several lesions in CBL.
Study Design
Patient Samples and DNA Extraction. All patients or their guardians provided informed consent for these studies according to the Declaration of Helsinki, and the experimental procedures were reviewed and approved by institutional review committees at each participating center. CMML patients were diagnosed and treated at MDACC. Genomic DNA was isolated using PureGene reagents (Qiagen, Valencia, CA). A clinical history of NF1 was available for some, but not all, patients. DNA from 40 anonymous, normal controls was also analyzed.
Single Nucleotide Polymorphism Array Analysis. 500 ng of sample DNA was analyzed using Affymetrix 6.0 SNP arrays as previously described [15] [16] [17] . Extraction and summarization of SNP/CNV probe hybridization intensities from CEL files was performed in dChip 18 , and normalization was performed using a "reference normalization" algorithm that uses only probes from chromosomes known or predicted to be diploid to guide array normalization 19 . Additional details on the bioinformatic and statistical analyses are included in Supplementary Materials. [20] [21] [22] . Polymerase chain reaction (PCR) amplification of CBL exons 8 and 9 was performed using primers and conditions listed in Table S1 . PCR products were visualized, purified, and sequenced according to standard methodologies. CFU-GM colonies were grown according to previously published methods 23 .
Statistical Methods.
The Chi-squared-test was used to examine the statistical significance of a relationship between categorical variables. Because a normal distribution cannot be assumed, median values and ranges were reported and nonparametric statistics were used to test for differences in continuous variables for different subgroups (Kruskal-Wallis test with subsequent post-hoc Mann-Whitney-U-Test). All p values were two-sided and values <0.05 were considered statistically significant. P values >0.1 were reported as nonsignificant, whereas those between 0.05 and 0.1 were reported in detail. No adjustment of the alpha-level to account for multiple testing was performed because of the explorative nature of the statistical analysis and the limited patient numbers available with clinical data.
Results and Discussion
We analyzed 27 JMML samples enriched for patients without known Ras pathway mutations for regions of copy-neutral LOH and detected 11q UPD in 5 cases (Figs. 1A and S1). Based on recent reports of CBL mutations in patients with other myeloid malignancies, we sequenced exons 8 and 9 of CBL in 26/27 of the patients that had For personal use only. on November 16, 2017. by guest www.bloodjournal.org From SNP arrays performed (there was one patient without DNA available for sequencing but this patient did not exhibit 11q UPD) and in an additional 133 JMML samples [10] [11] [12] [13] [14] . CBL sequencing data revealed 25 homozygous and 2 heterozygous mutations ( Fig. 1C and Table 1 ) located throughout the linker and RING finger domain, with the predominantly affected codon in JMML being the tyrosine residue at position 371 (Y371) ( Fig. 1C and Table 1 ). No mutations were identified in 40 normal controls.
One patient who was diagnosed at 7 months of age (HM1854) had an umbilical cord blood sample available for genotyping ( Fig. 1C ). Interestingly, DNA isolated from mononuclear cells at diagnosis demonstrated a homozygous Y371H while DNA isolated from her cord blood demonstrated a heterozygous mutation (Fig. 1C) . Similarly, SNP analysis of the diagnostic sample revealed 11q isodisomy, which was absent in the cord blood sample (Fig. 1C ). DNA extracted from hypersensitive CFU-GM colonies plucked from cells propagated at diagnosis revealed that 10/16 colonies harbored homozygous lesions while 6 were heterozygous. Furthermore, an aliquot of cord blood was defrosted and plated on methylcellulose, and a spectrum of CFU-GEMM, BFU-E, CFU-E, and CFU-GM colonies genotyped, with almost all colonies demonstrating the heterozygous CBL mutation.
In a second patient (HM1658), an Epstein-Barr virus-transformed cell line also harbored the identical homozygous Y371H alteration seen in DNA from diagnosis.
However, previous data suggests that B cells are only rarely involved in the JMML clone 24 . Hypersensitive CFU-GM colonies picked at diagnosis were largely homozygous for the CBL mutation (9 of 13 tested) but the rest were heterozygous. Finally, in a third patient (HM1993), DNA isolated from the buccal mucosa demonstrated a heterozygous For personal use only. on November 16, 2017. by guest www.bloodjournal.org From lesion, while the majority of CFU-GM colonies again demonstrated homozygous lesions (while the rest were heterozygous). Together, these data support the hypothesis that reduplication of an inherited CBL mutation in a pluripotent hematopoietic stem cell confers a selective advantage for the homozygous state and also raise the possibility of germline lesions in some patients with CBL mutations.
Consistent with other reports we also detected CBL mutations in five of 44 CMML samples (Table S2) 10, 11 . None of the specimens in this cohort with a RAS mutation (n=15) also had a CBL mutation. However, one CMML patient had a mutation in both JAK2 (V617F) and CBL. In contrast to JMML, we and others found no Y371 alterations in CMML 10, 11 .
We specifically assessed the frequency of CBL mutations in a subset of 68 JMML cases without mutations in RAS or PTPN11. Forty-five of these patients had no clinical evidence of NF1, and the NF1 status was unknown in the other 23. We identified 27 CBL mutations (39.7%). These data demonstrate CBL mutations in 10-15% of JMML patients overall, which is similar to the frequency of NF1 mutations. Importantly, we did not detect any CBL mutations in 91 JMML samples with known mutations in RAS or PTPN11. The difference in the frequency of CBL mutations in JMML patients without mutations in either RAS, PTPN11, or NF1 (27/68) versus those with a known RAS or PTPN11 mutation (0/91) was highly significant (Fisher's exact test, p<0.00001).
We also compared the clinical features at diagnosis of patients with CBL mutations versus those with either a RAS, PTPN11, or no known mutation ( Table 2 ) and found that there was a tendency for CBL mutated patients to present at a younger age (p=0.09), though this was not statistically significant. Interestingly, there were no cases For personal use only. on November 16, 2017. by guest www.bloodjournal.org From of monosomy 7 in the CBL group; however, this was also not statistically significant.
While there were also no significant differences in overall survival among the mutation groups, our sample size is not sufficiently large enough to detect modest differences.
Future prospective analyses of genotype/phenotype correlations will therefore be necessary in order to extend these findings.
In previous studies of phospho-signaling networks in JMML, we evaluated 10 specimens from patients with known KRAS, NRAS, PTPN11, or NF1 mutations and four without a known Ras pathway lesion 9 . DNA sequence analysis revealed CBL mutations in three of these four patients. These three cases exhibited a similar pattern of CFU-GM hypersensitivity in methylcellulose cultures and expressed high levels of pSTAT5 in response to low doses of GM-CSF, similar to other JMML patients with somatic mutations in RAS/PTPN11 or NF1 (the three cases with CBL mutations are HM1661, 1854, and 1993 in Ref. 10 ).
c-Cbl primarily functions as an E3 ubiquitin ligase and is responsible for the intracellular transport and degradation of a large number of receptor tyrosine kinases but also retains important adaptor functions (reviewed in 25, 26 ). Approximately 150 proteins associate with or are regulated by c-Cbl (reviewed in 25 ). Among these proteins is Grb2, an adaptor molecule that binds to c-Cbl and prevents it from binding to SOS, a known guanine nucleotide exchange factor for Ras 27 . CBL mutations reported in myeloid malignancies uniformly affect either the linker region or the RING finger domain 10, [12] [13] [14] . Loss of ubiquitination of activated receptor tyrosine kinases is thought to contribute to the transforming potential of leukemia-associated mutant CBL proteins 14 .
Mutations that affect Y371 are rare in acute myeloid leukemia 28 ; however, expressing For personal use only. on November 16, 2017. by guest www.bloodjournal.org From this mutant Cbl protein with Flt3 in BaF3 cells induced cytokine independent growth and survival. Mutation Y368 or Y371 could confer substantial structural changes to the TKB domain that could ultimately affect binding partners with different consequences 29 . For example, Y371F abolishes E3 ligase activity while substitution to glutamic acid confers constitutive activation 30, 31 . In addition, Y371 mediates binding of c-Cbl to the p85 regulatory subunit of PI3 kinase 32 , and the Y371F abolishes this interaction.
The identification of homozygous CBL mutations in JMML suggests that CBL is a new tumor suppressor gene. Cells from these patients display identical GM-CSF hypersensitivity and pSTAT5 signaling as other known Ras pathway mutations.
Moreover, the known molecular genetic and biochemical features of JMML and our data
showing that CBL, PTPN11, KRAS, and NRAS are mutually exclusive imply that leukemia-associated CBL mutations result in hyperactive Ras. These effects of c-Cbl could be mediated by failure of the mutant protein to efficiently target one or more cytokine receptors for degradation by ubiquitination by an alternative biochemical mechanism. Along these lines, it is of interest that Y371 is a "hot spot" for CBL mutations in JMML that is rarely mutated in other myeloid malignancies, and that the vast majority of the mutations detected are missense substitutions or in frame deletions resulting in a translated protein that may retain some function. Further work will be necessary to unravel the biochemical effects of these mutants on Ras networks and on other growth control pathways. 
